Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Post by ronrydellon Sep 25, 2013 11:15am
269 Views
Post# 21766163

AGM Continued

AGM ContinuedJust to confirm...getting the right questions asked...that are germane to giving us 1) hope 2) moving the stock price and 3) a reasonable value proposition is what would be helpful. 

It's good to keep in mind that positive opinions, no matter how well intentioned, does NOT move the stock. RVX is like an old worn out shoe now with all the time that has passed in the eyes of long time shareholders and is long forgotten in the daily scheme of things by the general public. Not to be caustic or disrespectful at all but share price and current lack of continued information is what it is. One dollar a share will be a great short term AND long term goal. 

History is NOT on our side when looking at startup up biotechs. It's almost like having to win the lottery! Having said all this I hope the attendees at the AGM press management with the hard questions. At the end of the day..in the years ahead, we will all be dependent on patients personal physicians to recommend and prescribe this drug AFTER a great Phase III and AFTER it get FDA approval and AFTER a great national marketing and public awareness program.

Best Case: it will be years (most of us won't still be alive) before the revenues earned by big Pharma will justify the huge 1) upfront payment and milestone payments and 2) the cash outlay for Phase III.

We need management to address these comments and shoot them down and tell us (me) how wrong  I am to even be thinking this way. I'm an empty cup wanting to learn...do not respond positively to mindless pumping and well intentioned opinions..just the facts please.
Bullboard Posts